Is neoadjuvant therapy necessary for resectable pancreatic cancer? A review of randomized controlled trials to date: a narrative review.

Perioperative systemic therapy, administered either preoperatively (neoadjuvant therapy) or postoperatively (adjuvant therapy), has been considered a strategy to improve the long-term prognosis of pancreatic cancer. While adjuvant therapy following r…

Preview only. Read the full abstract at the source